Median effective target effect-site concentration of sufentanil inhibiting cardiovascular response to tracheal intubation when combined with propofol in patients of Uygur nationality
10.3760/cma.j.issn.0254-1416.2013.01.012
- VernacularTitle:复合异丙酚时舒芬太尼抑制维吾尔族患者气管插管心血管反应的半数有效效应室靶浓度
- Author:
Zhengang CAO
;
Li TANG
;
Yi ZHOU
;
Mingming SUN
;
Changjian GU
;
Xincheng LI
- Publication Type:Journal Article
- Keywords:
Sufentanil;
Propofol;
UYGUR NATIONALITY;
Dose-response relationship,drug;
Drug delivery systems
- From:
Chinese Journal of Anesthesiology
2013;(1):49-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the median effective target effect-site concentration (EC50) of sufentanil inhibiting cardiovascular response to tracheal intubation when combined with propofol in patients of Uygur nationality.Methods Thirty-one ASA Ⅰ or Ⅱ Uighurs of both sexes,aged 21-59 yr,with body mass index 18-28 kg/m2,undergoing elective surgery,were enrolled in this study.Anesthesia was induced and maintained with propofol and sufentanil target-controlled infusion and iv injection of cisatracurium 0.2 mg/kg.The target effect-site concentration (Ce) of propofol was set at 3.0 μg/ml.Tracheal intubation was performed after the target Ce and plasma concentrations were balanced.The target Ce was set at 0.8 ng/ml in the first patient.Each time Ce increased/decreased by 10％ in the next patient depending on whether or not the cardiovascular response to tracheal intubation occurred.The positive cardiovascular response was defined as increase in systolic blood pressure by 15％ and/or HR＞ 90 bpm lasting for ＞ 15 s.The EC50(95％ confidence interval) of sufentanil blunting cardiovascular responses to trancheal intubation was calculated by Probit analysis.Results EC50 (95 ％ confidence interval) of sufentanil inhibiting cardiovascular response to tracheal intubation when combined with 3.0 μg/ml propofol was 0.46 (0.43-0.49) ng/ml.Conclusion EC50 of sufentanil inhibiting cardiovascular response to tracheal intubation is 0.46 ng/ml in patients of Uygur nationality when combined with propofol.
